Generic Sweden (GENI) investor relations material

Executive summary

• Net sales increased by 9.9% to 48.7 MSEK in Q2 2026 and by 9.5% to 97.6 MSEK for H1 2026 compared to the same periods last year.

• Gross profit rose 10.9% in Q2 and 9.6% in H1, with gross margins stable at 44.2% and 44.0% respectively.

• EBIT grew by 3.3% in Q2 and 2.0% in H1, with EBIT margins slightly lower year-over-year due to higher external and personnel costs.

• Cash flow from operations was 12.2 MSEK in Q2 and 10.5 MSEK in H1, with liquidity and equity positions strengthened.

Financial highlights

• Q2 net sales: 48.7 MSEK (+9.9% YoY); H1 net sales: 97.6 MSEK (+9.5% YoY).

• Q2 gross profit: 21.5 MSEK (+10.9% YoY); H1 gross profit: 42.9 MSEK (+9.6% YoY).

• Q2 EBIT: 9.3 MSEK (+3.3% YoY); H1 EBIT: 19.1 MSEK (+2.0% YoY).

• Q2 EPS: 0.64 SEK (0.58 SEK prior year); H1 EPS: 1.27 SEK (1.21 SEK prior year).

• Cash and cash equivalents at period end: 45.8 MSEK (22.2 MSEK prior year).

Outlook and guidance

• Continued focus on organic growth, platform development, and expanding customer base in core segments.

• Ongoing investments in security, automation, and product leadership to support future growth.

• No new significant risks identified since the last annual report.